Nothing Special   »   [go: up one dir, main page]

BR112018008931A2 - ?compostos para tratamento de distúrbios hipoproliferativos? - Google Patents

?compostos para tratamento de distúrbios hipoproliferativos?

Info

Publication number
BR112018008931A2
BR112018008931A2 BR112018008931A BR112018008931A BR112018008931A2 BR 112018008931 A2 BR112018008931 A2 BR 112018008931A2 BR 112018008931 A BR112018008931 A BR 112018008931A BR 112018008931 A BR112018008931 A BR 112018008931A BR 112018008931 A2 BR112018008931 A2 BR 112018008931A2
Authority
BR
Brazil
Prior art keywords
compounds
hypoproliferative disorders
treating
disorders
treating hypoproliferative
Prior art date
Application number
BR112018008931A
Other languages
English (en)
Other versions
BR112018008931A8 (pt
Inventor
Flygare Johan
Johansson Lars
Lundbäck Thomas
Original Assignee
Lu License Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lu License Ab filed Critical Lu License Ab
Publication of BR112018008931A2 publication Critical patent/BR112018008931A2/pt
Publication of BR112018008931A8 publication Critical patent/BR112018008931A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção se refere ao uso de inibidores de cdk8 e/ou cdk19 no tratamento de ribossomopatias, bem como a condições caracterizadas por número reduzido de células tronco hematopoéticas e/ou células progenitoras; e distúrbios anabólicos ósseos.
BR112018008931A 2015-11-03 2016-11-03 ?compostos para tratamento de distúrbios hipoproliferativos? BR112018008931A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1551419 2015-11-03
PCT/EP2016/076550 WO2017076968A1 (en) 2015-11-03 2016-11-03 Compounds for treatment of hypoproliferative disorders

Publications (2)

Publication Number Publication Date
BR112018008931A2 true BR112018008931A2 (pt) 2018-11-06
BR112018008931A8 BR112018008931A8 (pt) 2019-02-26

Family

ID=57326350

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008931A BR112018008931A8 (pt) 2015-11-03 2016-11-03 ?compostos para tratamento de distúrbios hipoproliferativos?

Country Status (11)

Country Link
US (1) US11471446B2 (pt)
EP (1) EP3370720A1 (pt)
JP (1) JP6977238B2 (pt)
KR (1) KR20180073600A (pt)
CN (1) CN108348509A (pt)
AU (1) AU2016348659B2 (pt)
BR (1) BR112018008931A8 (pt)
CA (1) CA3002495A1 (pt)
IL (1) IL258593B (pt)
MX (1) MX2018005158A (pt)
WO (1) WO2017076968A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
EP3917523B1 (en) * 2019-02-01 2024-09-11 University of South Carolina Bicyclic pyridine compounds for use in treating cancer
WO2020237014A1 (en) * 2019-05-21 2020-11-26 University Of South Carolina 3-amino-4-(4-(4 (dimethylcarbamoyl) phenyl)-1,4-diazepan-1-yl) thieno [2,3-b] pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same
GB202208226D0 (en) * 2022-06-06 2022-07-20 Royal Veterinary College Method and treatment for osteoarthritis and diseases of chondrocyte hypertrophy
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof
WO2024193640A1 (zh) * 2023-03-22 2024-09-26 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27834A1 (es) * 2002-06-06 2003-12-31 Boehringer Ingelheim Pharma Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos.
WO2005100365A1 (ja) 2004-04-12 2005-10-27 Sankyo Company, Limited チエノピリジン誘導体
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
UA112197C2 (uk) * 2011-09-13 2016-08-10 Ігор Ронінсон СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАНЬ АБО ПОРУШЕНЬ, СПРИЧИНЮВАНИХ ІНДУКОВАНОЮ ТРАНСКРИПЦІЙНОЮ АКТИВНІСТЮ NF-kB
EP2809324B1 (en) * 2012-02-02 2018-08-01 Senex Biotechnology, Inc. Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer
US9827252B2 (en) 2012-03-16 2017-11-28 Children's Medical Center Corporation Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
KR20150044952A (ko) 2012-08-23 2015-04-27 에프. 호프만-라 로슈 아게 암의 치료를 위한 신규한 페닐-피리딘/피라진 아미드
GB201220157D0 (en) 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
EP2928893A1 (en) 2012-12-10 2015-10-14 F. Hoffmann-La Roche AG Novel bi-ring phenyl-pyridines/pyrazines for the treatment of cancer
WO2014106606A1 (en) 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
WO2014154723A1 (en) 2013-03-29 2014-10-02 F. Hoffmann-La Roche Ag Novel pyrrole derivatives for the treatment of cancer
WO2014194201A2 (en) 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof
US9926319B2 (en) 2014-03-27 2018-03-27 Merck Patent Gmbh Pyridyl piperidines

Also Published As

Publication number Publication date
CN108348509A (zh) 2018-07-31
WO2017076968A1 (en) 2017-05-11
IL258593B (en) 2021-04-29
AU2016348659B2 (en) 2022-07-28
US20190111034A1 (en) 2019-04-18
KR20180073600A (ko) 2018-07-02
AU2016348659A1 (en) 2018-05-31
BR112018008931A8 (pt) 2019-02-26
EP3370720A1 (en) 2018-09-12
US11471446B2 (en) 2022-10-18
IL258593A (en) 2018-06-28
JP2018532784A (ja) 2018-11-08
CA3002495A1 (en) 2017-05-11
MX2018005158A (es) 2019-05-16
JP6977238B2 (ja) 2021-12-08

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
CO2017011851A2 (es) Compuestos novedosos
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
NI201600071A (es) Compuestos de inhibidor de autotaxina
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX2015010125A (es) Derivados de piridazinona-amidas.
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
EP3598980A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
DOP2014000253A (es) Inhibidores del nampt
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
CL2015002897A1 (es) Inhibidores de bace1
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112017012581A2 (pt) tratamento de degeneração da retina com o uso de células progenitoras
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]